SI-Bone

SI-BONE makes implants to fix painful lower back issues. Small titanium devices help stabilize the spine and pelvis. Doctors use these tools to treat injuries and aging joints.

What's in the Toolkit?

• iFuse: Triangular titanium implants designed to stabilize joints and encourage bone growth to drive fusion.
• iFuse Bedrock Granite: Additively-manufactured device providing fusion and fixation at the base of spinal constructs.
• iFuse-TORQ: Threaded metal implants used for pelvic fractures and minimally invasive sacroiliac joint fusion.
• iFuse INTRA: Human tissue products used by physicians for joint stabilization and fusion procedures.

Expanding the Treatment Map

• Secured a New Technology Add-on Payment for iFuse TORQ TNT in October 2025 to increase hospital reimbursement.
• Expanded outpatient access for iFuse Bedrock Granite in January 2025 through the Medicare Transitional Pass-Through program.
• Entered an exclusive manufacturing and supply agreement with rms Company in February 2024.
• Launched the iFuse INTRA platform in February 2024 to broaden available clinical solutions.

Why Clinical Evidence Matters

The company maintains a specialized sales network of 172 direct employees and 320 third-party agents to reach 12,000 physicians. Its operations are supported by 180 published studies proving the safety and effectiveness of its bone fusion technology.

Check the Scorecard

• Revenue reached $56.4 million in Q4 2025, up 15% from Q4 2024.
• Operating income improved to -$2.5 million in Q4 2025, narrowing from -$5.5 million a year prior.
• Net income reached -$1.6 million in Q4 2025, an improvement of 63.3% year-over-year.
• Free cash flow turned positive at $440,000 in Q4 2025, up from -$1.1 million in Q4 2024.

Bottom Line

SI-BONE has evolved from a startup focused on a single joint to a broad technology platform for sacropelvic care. Its combination of clinical data and a growing product suite supports its expanding presence in the medical device market.